Login / Signup

Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.

Soo-Chin LeeJoseph J ZhaoYu Yang SoonAlvin WongFolefac AminkengYvonne AngYugarajah AsokumaranJia Li LowMatilda LeeJoan R E ChooGloria ChanAdrian KeeSen Hee TayBoon Cher GohRoss A Soo
Published in: Thoracic cancer (2022)
In this real-world study, durvalumab consolidation post CCRT was associated with a statistically significant improvement in PFS and OS. Effect of durvalumab on PFS was not modified by EGFR status. Active surveillance for pneumonitis is crucial. Baseline NLR may help to predict the benefit of treatment with durvalumab.
Keyphrases